Examine discharge data
Review files of patients with a discharge diagnosis of acute ischemic stroke (AIS)
Identify missed eligible patients
Determine eligibility according to Activase prescribing information
Compile reasons for non-treatment
Analyze trends for non-treatment of missed eligible patients
Share findings at regular team meetings
Develop strategies to help identify and treat all eligible patients
Execute quality improvement strategies
Continually track performance and outcomes, refine strategies
Frequent causes for slower treatment with Activase include difficulties in determining patient eligibility, delayed diagnoses, and in-hospital delays, which can add over 25 minutes to the door-to-needle time and negatively impact patient outcomes.
Based on your metrics, what is the common reason for not treating with Activase?
Delays in DTN time can impact patients.2
AIS is a serious medical emergency. Multiple parallel processes can help expedite treatment for patients with AIS who are eligible for Activase with or without subsequent mechanical thrombectomy.6,26-29
*Certain patient evaluations and diagnoses may be performed using telestroke services.27,29,31
†In centers without capabilities to perform mechanical thrombectomy, patients should begin receiving Activase before being transferred for treatment at an experienced stroke center.
CT=computed tomography; CTA=computed tomography angiogram; ED=emergency department; EMS=emergency medical services; LVO=large vessel occlusion.
What's your DTN target?
Five time-saving strategies employed by world-class hospitals to reduce DTN time include27:
Evaluating all patients with AIS is a better way to view and understand the full AIS patient pool at your institution. Healthcare professionals may have differing criteria when evaluating appropriateness for Activase treatment, based on:
Constant evaluation of processes implemented within an institution can have a meaningful impact in identifying missed eligible patients.
How do you use metric to identify missed eligible patients? What tools do you use?
Tracking every patient discharged from your hospital with a confirmed AIS diagnosis, tracking All-AIS, is a way to increase knowledge of the patient pool. It can provide valuable insights into understanding why patients at your institution may or may not be treated and help identify potential gaps.
Reasons for non-treatment may already be tracked at your institution. Hospitals using GWTG must document reasons for non-treatment for all AIS patients who did not receive Activase. Consider evaluating GWTG reports such as, Reasons for no intravenous Activase, illustrated in the sample below, as they can provide insights into critical trends regarding your patient pool.
When evaluating ALL‑AIS, does patient eligibility reflect what is currently in your hospital protocol? Is anything surprising?
How confident are you that non-treated patients were excluded for the right reasons?
National Institute of Neurological Disorders and Stroke. Know stroke. Know the signs. Act in time. National Institute of Neurological Disorders and Stroke website. http://www.ninds.nih.gov/disorders/stroke/knowstroke.htm. Last modified March 29, 2016. Accessed August 12, 2016.
National Institute of Neurological Disorders and Stroke. Know stroke. Know the signs. Act in time. National Institute of Neurological Disorders and Stroke website. http://www.ninds.nih.gov/disorders/stroke/knowstroke.htm. Last modified March 29, 2016. Accessed August 12, 2016.
Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019;50:e344-e418.
Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019;50:e344-e418.
Demaerschalk BM, Kleindorfer DO, Adeoye OM, et al. Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2016;47(2):581-641.
Demaerschalk BM, Kleindorfer DO, Adeoye OM, et al. Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2016;47(2):581-641.
Ferbert A, Brückmann H, Drummen R. Clinical features of proven basilar artery occlusion. Stroke. 1990;21(8):1135-1142. doi:10.1161/01.str.21.8.1135
Ferbert A, Brückmann H, Drummen R. Clinical features of proven basilar artery occlusion. Stroke. 1990;21(8):1135-1142. doi:10.1161/01.str.21.8.1135
Kattah JC, Talkad AV, Wang DZ, et al. HINTS to diagnose stroke in the acute vestibular syndrome: three-step bedside oculomotor examination more sensitive than early MRI diffusion-weighted imaging. Stroke. 2009;40(11):3504-10.
Kattah JC, Talkad AV, Wang DZ, et al. HINTS to diagnose stroke in the acute vestibular syndrome: three-step bedside oculomotor examination more sensitive than early MRI diffusion-weighted imaging. Stroke. 2009;40(11):3504-10.
Activase [prescribing information]. South San Francisco, CA: Genentech, Inc.
Activase [prescribing information]. South San Francisco, CA: Genentech, Inc.
Arch AE, Weisman DC, Coca S, et al. Missed ischemic stroke diagnosis in the emergency department by emergency medicine and neurology services. Stroke. 2016;47(3):668-73.
Arch AE, Weisman DC, Coca S, et al. Missed ischemic stroke diagnosis in the emergency department by emergency medicine and neurology services. Stroke. 2016;47(3):668-73.
Madsen TE, Khoury J, Cadena R, et al. Potentially missed diagnosis of ischemic stroke in the emergency department in the Greater Cincinnati/Northern Kentucky stroke study. Academic Emergency Medicine. 2016;23(10):1128-35.
Madsen TE, Khoury J, Cadena R, et al. Potentially missed diagnosis of ischemic stroke in the emergency department in the Greater Cincinnati/Northern Kentucky stroke study. Academic Emergency Medicine. 2016;23(10):1128-35.
Masoud HE, de Havenon A, Castonguay AC et al. 2022 brief practice update on intravenous thrombolysis before thrombectomy in patients with large vessel occlusion acute ischemic stroke: a statement from Society of Vascular and Interventional Neurology Guidelines and Practice Standards (GAPS) committee. Stroke Vasc Interv Neurol. 2022;2:e000276. doi:10.1161/SVIN.121.000276
Masoud HE, de Havenon A, Castonguay AC et al. 2022 brief practice update on intravenous thrombolysis before thrombectomy in patients with large vessel occlusion acute ischemic stroke: a statement from Society of Vascular and Interventional Neurology Guidelines and Practice Standards (GAPS) committee. Stroke Vasc Interv Neurol. 2022;2:e000276. doi:10.1161/SVIN.121.000276
Trevo EDFU. Fremont, CA: Stryker International; 2016.
Trevo EDFU. Fremont, CA: Stryker International; 2016.
Solitaire Revascularization Device. Medtronic website. Updated February 2018. Accessed May 9, 2018. http://www.medtronic.com/us-en/healthcare-professionals/products/neurological/revascularization-stroke/solitaire.html
Solitaire Revascularization Device. Medtronic website. Updated February 2018. Accessed May 9, 2018. http://www.medtronic.com/us-en/healthcare-professionals/products/neurological/revascularization-stroke/solitaire.html
Food and Drug Administration. FDA information on medication errors involving Activase and TNKase. September 2015. Available at http://www.fda.gov. Accessed on February 24, 2023.
Food and Drug Administration. FDA information on medication errors involving Activase and TNKase. September 2015. Available at http://www.fda.gov. Accessed on February 24, 2023.
Data on file. Genentech USA. No Title.
Data on file. Genentech USA. No Title.
National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333:1581-1587.
National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333:1581-1587.
FDA Access Summary basis of approval. https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/altegen061896s.pdf. Accessed August 14, 2017.
FDA Access Summary basis of approval. https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/altegen061896s.pdf. Accessed August 14, 2017.
Summers D, Leonard A, Wentworth D, et al. Comprehensive overview of nursing and interdisciplinary care of the acute ischemic stroke patient: a scientific statement from the American Heart Association. Stroke. 2009;40:2911-2944.
Summers D, Leonard A, Wentworth D, et al. Comprehensive overview of nursing and interdisciplinary care of the acute ischemic stroke patient: a scientific statement from the American Heart Association. Stroke. 2009;40:2911-2944.
American Association of Neuroscience Nurses. Reference Series for Clinical Practice. 2004. Available at https://aann.org/. Accessed on February 23, 2023.
American Association of Neuroscience Nurses. Reference Series for Clinical Practice. 2004. Available at https://aann.org/. Accessed on February 23, 2023.
Tamm A, Siddiqui M, Shuaib A, et al. Impact of stroke care unit on patient outcomes in a community hospital. Stroke. 2014;45(1):211-216.
Tamm A, Siddiqui M, Shuaib A, et al. Impact of stroke care unit on patient outcomes in a community hospital. Stroke. 2014;45(1):211-216.
CMS Quality Measurement Programs Characteristics. Centers for Medicare and Medicaid Services website. https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/QualityMeasures/Downloads/CMSQualityMeasurementProgramsCharacteristics.PDF. Published June 28, 2012. Accessed August 13, 2016.
CMS Quality Measurement Programs Characteristics. Centers for Medicare and Medicaid Services website. https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/QualityMeasures/Downloads/CMSQualityMeasurementProgramsCharacteristics.PDF. Published June 28, 2012. Accessed August 13, 2016.
The Joint Commission, Stroke. Last updated June 17, 2016. Accessed August 1, 2016. https://www.jointcommission.org/stroke/
The Joint Commission, Stroke. Last updated June 17, 2016. Accessed August 1, 2016. https://www.jointcommission.org/stroke/
Skolarus LE, Meurer WJ, Shanmugasundaram K, et al. Marked regional variation in acute stroke treatment among Medicare beneficiaries. Stroke. 2015;46:1890-1896.
Skolarus LE, Meurer WJ, Shanmugasundaram K, et al. Marked regional variation in acute stroke treatment among Medicare beneficiaries. Stroke. 2015;46:1890-1896.
ICD-10. https://www.cms.gov/Medicare/Coding/ICD10/. Accessed August 14, 2017.
ICD-10. https://www.cms.gov/Medicare/Coding/ICD10/. Accessed August 14, 2017.
Schwamm LH, Pancioli A, Acker JE, et al. Recommendations for the establishment of stroke systems of care: recommendations from the American Stroke Association’s Task Force on the Development of Stroke Systems. Stroke. 2005;36(3):690-703.
Schwamm LH, Pancioli A, Acker JE, et al. Recommendations for the establishment of stroke systems of care: recommendations from the American Stroke Association’s Task Force on the Development of Stroke Systems. Stroke. 2005;36(3):690-703.
Fonarow GC, Smith EE, Saver JL, et al. Improving door-to-needle times in acute ischemic stroke: the design and rationale for the American Heart Association/American Stroke Association's Target: Stroke initiative. Stroke. 2011;42(10):2983-2989.
Fonarow GC, Smith EE, Saver JL, et al. Improving door-to-needle times in acute ischemic stroke: the design and rationale for the American Heart Association/American Stroke Association's Target: Stroke initiative. Stroke. 2011;42(10):2983-2989.
Goyal M, Menon BK, Hill MD, Demchuk A. Consistently achieving computed tomography to endovascular recanalization <90 minutes: solutions and innovations. Stroke. 2014;45(12):e252-e256.
Goyal M, Menon BK, Hill MD, Demchuk A. Consistently achieving computed tomography to endovascular recanalization <90 minutes: solutions and innovations. Stroke. 2014;45(12):e252-e256.
Kalanithi L, Tai W, Conley J, Platchek T, Zulman D, Milstein A. Better health, less spending: delivery innovation for ischemic cerebrovascular disease. Stroke. 2014;45(10):3105-3111.
Kalanithi L, Tai W, Conley J, Platchek T, Zulman D, Milstein A. Better health, less spending: delivery innovation for ischemic cerebrovascular disease. Stroke. 2014;45(10):3105-3111.
Meretoja A, Weir L, Ugalde M, et al. Helsinki model cut stroke thrombolysis delays to 25 minutes in Melbourne in only 4 months. Neurology. 2013;81(12):1071-1076.
Meretoja A, Weir L, Ugalde M, et al. Helsinki model cut stroke thrombolysis delays to 25 minutes in Melbourne in only 4 months. Neurology. 2013;81(12):1071-1076.
Nguyen-Huynh MN. KPNC stroke EXPRESS: expediting the process of evaluating and stopping stroke. Presentation; 2016.
Nguyen-Huynh MN. KPNC stroke EXPRESS: expediting the process of evaluating and stopping stroke. Presentation; 2016.
American Heart Association. Target: Stroke. Accessed April 10, 2023. https://www.heart.org/en/professional/quality-improvement/target-stroke
American Heart Association. Target: Stroke. Accessed April 10, 2023. https://www.heart.org/en/professional/quality-improvement/target-stroke
Wechsler LR, Demaerschalk BM, Schwamm LH, et al. Telemedicine quality and outcomes in stroke: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2017 Jan 1;48(1):e3-25.
Wechsler LR, Demaerschalk BM, Schwamm LH, et al. Telemedicine quality and outcomes in stroke: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2017 Jan 1;48(1):e3-25.
American Hospital Association. http://www.aha.org/research/reports/tw/12oct-tw-quality.pdf. October 2012. Accessed October 11, 2016.
American Hospital Association. http://www.aha.org/research/reports/tw/12oct-tw-quality.pdf. October 2012. Accessed October 11, 2016.
Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315-352.
Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315-352.
Fesmire FM, Brown MD, Espinosa JA, et al. Critical issues in the evaluation and management of adult patients presenting to the emergency department with suspected pulmonary embolism. Ann Emerg Med. 2011 Jun;57(6):628-652.e75.
Fesmire FM, Brown MD, Espinosa JA, et al. Critical issues in the evaluation and management of adult patients presenting to the emergency department with suspected pulmonary embolism. Ann Emerg Med. 2011 Jun;57(6):628-652.e75.
Wood KE. Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest. 2002;121:877-905.
Wood KE. Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest. 2002;121:877-905.
Tan KT, Oudkerk M, van Beek EJR. Deep Vein Thrombosis and Pulmonary Embolism. In: Hallet JW Jr, Mills JL, Earnshaw JJ, Reekers JA, eds. Comprehensive Vascular and Endovascular Surgery. Philadelphia, PA: Elsevier Limited; 2003.
Tan KT, Oudkerk M, van Beek EJR. Deep Vein Thrombosis and Pulmonary Embolism. In: Hallet JW Jr, Mills JL, Earnshaw JJ, Reekers JA, eds. Comprehensive Vascular and Endovascular Surgery. Philadelphia, PA: Elsevier Limited; 2003.
Martin-Schild S, Albright KC, Tanksley J, et al. Zero on the NIHSS does not equal the absence of stroke. Ann Emerg Med. 2011;57:42-45.
Martin-Schild S, Albright KC, Tanksley J, et al. Zero on the NIHSS does not equal the absence of stroke. Ann Emerg Med. 2011;57:42-45.
NIH Stroke Scale International. Approach to Human Subject Protection and Patient Safety. Available at: http://www.nihstrokescale.org. Accessed March 18, 2020.
NIH Stroke Scale International. Approach to Human Subject Protection and Patient Safety. Available at: http://www.nihstrokescale.org. Accessed March 18, 2020.
Centers for Disease Control and Prevention. MMWR. 2009 May 1;58:421-426.
Centers for Disease Control and Prevention. MMWR. 2009 May 1;58:421-426.
Menon BK, Saver JL, Prabhakaran S, et al. Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator. Stroke. 2012;43:2293-2299.
Menon BK, Saver JL, Prabhakaran S, et al. Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator. Stroke. 2012;43:2293-2299.
Searls DE, Pazdera L, Korbel E, Vysata O, Caplan LR. Symptoms and signs of posterior circulation ischemia in the New England Medical Center posterior circulation registry. Arch Neurol. 2012;69(3):346-351. doi:10.1001/archneurol.2011.2083
Searls DE, Pazdera L, Korbel E, Vysata O, Caplan LR. Symptoms and signs of posterior circulation ischemia in the New England Medical Center posterior circulation registry. Arch Neurol. 2012;69(3):346-351. doi:10.1001/archneurol.2011.2083
This video presents an overview of the steps required to diagnose acute ischemic stroke, including brain imaging. It also describes patient eligibility for Activase® treatment and presents some recommendations on how to enhance the efficacy of a stroke program.
This video provides a demonstration of the appropriate reconstitution, dosing, and administration of Activase for eligible acute ischemic stroke patients.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.